Literature DB >> 35120786

Additional insights on COVID-associated mucormycosis.

Prashanth Panta1.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 35120786      PMCID: PMC8591849          DOI: 10.1016/j.bjoms.2021.09.020

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   2.018


× No keyword cloud information.
Sir, The response letter by Arakeri et al was a good read. In the original paper, the authors mentioned that mucormycosis has been found to be linked to COVID-19 infections caused by the B.1.617.2 (Delta) variant. The Delta-mucor hypothesis gained importance due to the unusual surge noticed during Indian’s second wave; however, its scientific basis still needs to be established. Direct Delta variant-associated immune dysregulation and metabolic dysfunction is a relatively minor mechanism in the absence of other potential contributors (evidenced by the low percentage of mucor cases seen in asymptomatic and untreated COVID patients). Such cases form a unique subset and deserve deeper exploration. The SARS-COV-2 virus may tend to infiltrate the pancreatic islets, leading to the genesis of hyperglycaemia and/or diabetes. However, we are unsure if there is any actual evidence that the Delta variant, in particular, has a significant adverse impact compared to other variants. If we show these comparative data on the pancreatic islets through cell-line or animal studies, we can more confidently explain why cases increased during the second wave. More countries are showing mucor cases; however, the numbers in India greatly exceeded all other nations (>45000 cases). This means we should look for India-specific factors, ranging from the geographic distribution of mucor-causing organisms, specific host factors, and even the medical management protocols deployed during that time. If we study the dosing of steroids during the first and second waves (through an analysis of medical prescriptions), our understanding could further improve. Steam inhalation practice (rampant during the pandemic) could have also resulted in heat injury to the nasal epithelium, enabling infection with the ubiquitous mucor organisms. However, very few case reports exist on this topic. Furthermore, a recent pre-print shows a lack of association. Another source of mucosal trauma could be repeated ‘nasopharyngeal swabbing.’ Although it seems unlikely, a pre-print indicates that this could be independently associated with a higher risk of COVID-associated mucormycosis (CAM). Prolonged oxygen administration could be another important source of trauma to the protective mucosal barrier. The connection between mask behaviour and mucormycosis also deserves a more committed exploration. Due to financial issues and general difficulty associated with N-95 mask use, many relied on low-cost cloth and surgical masks and frequently reused them. The cloth masks, in particular, could serve as a reservoir of fungal spores. Their mesh-like design could entrap and accumulate the free-floating spores that might eventually settle within the nasal passages during air exchange, and germinate once tissue conditions become conducive. A hyperglycaemic and immunosuppressive state induced by diabetes and/or high-dose and prolonged corticosteroid therapy constitute the favourable tissue milieu. Alongside explorations into steroid use, mode of oxygen administration, comorbidities (eg, diabetes, renal disease), immunosuppressant use, future efforts must be strategically planned to address the role of viral variants, mask practices, steam inhalation, nasopharyngeal swabbing, exposure to gardening activities, and indoor/outdoor pollution (environmental fungal contamination). It is noteworthy that different contributors act simultaneously.

Conflict of interest

We have no conflicts of interest.

Financial disclosure

None declared.

Funding

None declared.

Ethics statement/confirmation of patients permission

Not applicable.
  4 in total

1.  COVID-associated mucormycosis (CAM) in India is a multidimensional problem.

Authors:  Prashanth Panta; Neil Stone
Journal:  Br J Oral Maxillofac Surg       Date:  2021-09-15       Impact factor: 2.018

2.  COVID-19 associated mucormycosis (CAM) in India: a formidable challenge.

Authors:  Vishal U S Rao; Gururaj Arakeri; Gaurav Madikeri; Ashwin Shah; Rachel S Oeppen; Peter A Brennan
Journal:  Br J Oral Maxillofac Surg       Date:  2021-06-29       Impact factor: 2.018

3.  Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1.

Authors:  Mrittika Sen; Santosh G Honavar; Rolika Bansal; Sabyasachi Sengupta; Raksha Rao; Usha Kim; Mukesh Sharma; Mahipal Sachdev; Ashok K Grover; Abhidnya Surve; Abhishek Budharapu; Abhishek K Ramadhin; Abhishek Kumar Tripathi; Adit Gupta; Aditya Bhargava; Animesh Sahu; Anjali Khairnar; Anju Kochar; Ankita Madhavani; Ankur K Shrivastava; Anuja K Desai; Anujeet Paul; Anuradha Ayyar; Aparna Bhatnagar; Aparna Singhal; Archana Sunil Nikose; Arun Bhargava; Arvind L Tenagi; Ashish Kamble; Ashiyana Nariani; Bhavin Patel; Bibbhuti Kashyap; Bodhraj Dhawan; Busaraben Vohra; Charuta Mandke; Chinmayee Thrishulamurthy; Chitra Sambare; Deepayan Sarkar; Devanshi Shirishbhai Mankad; Dhwani Maheshwari; Dilip Lalwani; Dipti Kanani; Diti Patel; Fairooz P Manjandavida; Frenali Godhani; Garima Amol Agarwal; Gayatri Ravulaparthi; Gondhi Vijay Shilpa; Gunjan Deshpande; Hansa Thakkar; Hardik Shah; Hare Ram Ojha; Harsha Jani; Jyoti Gontia; Jyotika P Mishrikotkar; Kamalpreet Likhari; Kamini Prajapati; Kavita Porwal; Kirthi Koka; Kulveer Singh Dharawat; Lakshmi B Ramamurthy; Mainak Bhattacharyya; Manorama Saini; Marem C Christy; Mausumi Das; Maya Hada; Mehul Panchal; Modini Pandharpurkar; Mohammad Osman Ali; Mukesh Porwal; Nagaraju Gangashetappa; Neelima Mehrotra; Neha Bijlani; Nidhi Gajendragadkar; Nitin M Nagarkar; Palak Modi; Parveen Rewri; Piyushi Sao; Prajakta Salunkhe Patil; Pramod Giri; Priti Kapadia; Priti Yadav; Purvi Bhagat; Ragini Parekh; Rajashekhar Dyaberi; Rajender Singh Chauhan; Rajwinder Kaur; Ram Kishan Duvesh; Ramesh Murthy; Ravi Varma Dandu; Ravija Kathiara; Renu Beri; Rinal Pandit; Rita Hepsi Rani; Roshmi Gupta; Ruchi Pherwani; Rujuta Sapkal; Rupa Mehta; Sameeksha Tadepalli; Samra Fatima; Sandeep Karmarkar; Sandeep Suresh Patil; Sanjana Shah; Sankit Shah; Sapan Shah; Sarika Dubey; Saurin Gandhi; Savitha Kanakpur; Shalini Mohan; Sharad Bhomaj; Sheela Kerkar; Shivani Jariwala; Shivati Sahu; Shruthi Tara; Shruti Kochar Maru; Shubha Jhavar; Shubhda Sharma; Shweta Gupta; Shwetha Kumari; Sima Das; Smita Menon; Snehal Burkule; Sonam Poonam Nisar; Subashini Kaliaperumal; Subramanya Rao; Sudipto Pakrasi; Sujatha Rathod; Sunil G Biradar; Suresh Kumar; Susheen Dutt; Svati Bansal; Swati Amulbhai Ravani; Sweta Lohiya; Syed Wajahat Ali Rizvi; Tanmay Gokhale; Tatyarao P Lahane; Tejaswini Vukkadala; Triveni Grover; Trupti Bhesaniya; Urmil Chawla; Usha Singh; Vaishali L Une; Varsha Nandedkar; Venkata Subramaniam; Vidya Eswaran; Vidya Nair Chaudhry; Viji Rangarajan; Vipin Dehane; Vivek M Sahasrabudhe; Yarra Sowjanya; Yashaswini Tupkary; Yogita Phadke
Journal:  Indian J Ophthalmol       Date:  2021-07       Impact factor: 1.848

4.  COVID-associated mucormycosis (CAM): is the Delta variant a cause?

Authors:  Gururaj Arakeri; Vishal Rao Us; Rui Amaral Mendes; Rachel S Oeppen; Peter A Brennan
Journal:  Br J Oral Maxillofac Surg       Date:  2021-09-16       Impact factor: 2.018

  4 in total
  1 in total

1.  Pathogenesis of COVID-19-associated mucormycosis (CAM) in India: probing the triggering factors.

Authors:  Gururaj Arakeri; Shreyas Patil; Vishal Rao Us; Rui Amaral Mendes; Rachel S Oeppen; Peter A Brennan
Journal:  Br J Oral Maxillofac Surg       Date:  2021-11-15       Impact factor: 2.018

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.